

## APPENDIX A

1. (amended) A method for inhibiting cancer cell growth or killing cancer cells comprising eliciting an immune response with an immunologically effective amount of a composition comprising a [phosphatidylserine/ polypeptide] lipid or lipid/polypeptide conjugate.
2. The method of claim 1, wherein said cancer cell is a lymphoid, renal or bladder cancer cell.
3. The method of claim 1, wherein said cancer cell is comprised within an animal.
4. The method of claim 3, wherein said animal is a human.
5. The method of claim 1, wherein said composition further comprises a pharmaceutical excipient.
6. The method of claim 5, wherein said composition is administered to said human topically, parenterally, orally, subcutaneously, or by direct injection into a tissue site.
7. (amended) The method of claim 1, wherein said [polypeptide is] immune response is elicited with lipid/polypeptide conjugate comprising a polypeptide selected from the group consisting of BSA, KLH, BGG, diphtheria toxin, and  $\beta$ 2-glycoprotein I.
8. The method of claim 7, wherein said polypeptide is  $\beta$ 2-glycoprotein I.
11. (amended) The method of claim [8] 7, wherein said lipid is phosphatidylcholine or phosphatidylserine.
12. A method of generating an immune response, comprising administering to an animal a pharmaceutical composition comprising an immunologically effective amount of a phosphatidylcholine/polypeptide or a phosphatidylserine/polypeptide conjugate composition.

A

28. The method of claim 1, wherein said lipid or lipid/polypeptide conjugate is phosphatidylserine or a phosphatidylserine/polypeptide conjugate.
29. The method of claim 3, wherein said animal has cancer.
30. The method of claim 29, wherein said animal has a tumor.
31. The method of claim 4, wherein said human has cancer.
32. The method of claim 31, wherein said human has a tumor.
33. The method of claim 12, wherein said animal comprises a cancer cell.
34. The method of claim 33, wherein said cancer cell is a lymphoid, renal or bladder cancer cell.
35. The method of claim 12, wherein said animal has cancer.
36. The method of claim 12, wherein said animal has a tumor.
37. The method of claim 12, wherein said animal is a human.
38. The method of claim 37, wherein said human has cancer.
39. The method of claim 40, wherein said human has a tumor.
40. The method of claim 12, wherein said animal is a mouse.
41. The method of claim 12, wherein said animal is a rat, a hamster, a guinea pig or a goat.
42. The method of claim 12, wherein said composition is administered to said animal topically, parenterally, orally, subcutaneously, or by direct injection into a tissue site.

43. The method of claim 12, wherein said immune response is elicited with a lipid or lipid/polypeptide conjugate comprising a polypeptide selected from the group consisting of BSA, KLH, BGG, diphtheria toxin, and  $\beta$ 2-glycoprotein I.

44. The method of claim 44, wherein said polypeptide is  $\beta$ 2-glycoprotein I.